Alector, Inc. - Common Stock (ALEC)

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.

Let's have a look at the gap up and gap down stocks in today's session.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.